Amantadine extended-release formulation is the first and only treatment option approved by the FDA for the treatment of dyskinesias in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
See Management: approach See Management: treatment algorithmAssistant Professor
Department of Neurology
Division of Movement Disorders
Northwestern University Feinberg School of Medicine
Chicago
IL
DB serves on the speaker's bureau for Teva Pharmaceuticals, and ACADIA Pharmaceutical, Inc. He has received consultancy fees from US WorldMeds and grant support from the Parkinson Foundation. He is on the board of directors for Rock Steady Boxing Windy City.
Dr Danny Bega would like to gratefully acknowledge Dr Meredith Spindler, Dr Jayne R. Wilkinson, and Dr Andrew D. Siderowf, the previous contributors to this monograph. MS, JRW, and ADS declare that they have no competing interests.
Assistant Clinical Professor
Department of Neurology
UCSF Medical Center
Parkinson's Disease Research
Education and Clinical Center
San Francisco
CA
GAG declares that he has no competing interests.
Assistant Professor of Neurology
Jefferson Medical College
Thomas Jefferson University
Philadelphia
PA
DK declares that he has no competing interests.
Consultant Neurologist / Honorary Senior Lecturer
Institute of Neurological Sciences
Southern General Hospital / University of Glasgow
Glasgow
UK
DG is an author of a reference cited in this monograph.
Reader in Clinical Neurology
Honorary Consultant
Institute of Neurology
National Hospital for Neurology and Neurosurgery
London
UK
PDL declares that she has no competing interests.
Assistant Professor
Department of Neurology
University of Florida College of Medicine
Gainesville
FL
NM declares that he has no competing interests.
Use of this content is subject to our disclaimer